SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:4e2aa643-56e2-4ce7-b10a-067f085454c3"
 

Search: onr:"swepub:oai:lup.lub.lu.se:4e2aa643-56e2-4ce7-b10a-067f085454c3" > Factors for glaucom...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Factors for glaucoma progression and the effect of treatment - The Early Manifest Glaucoma Trial

Leske, MC (author)
Heijl, Anders (author)
Lund University,Lunds universitet,Oftalmologi (Malmö),Forskargrupper vid Lunds universitet,Ophthalmology (Malmö),Lund University Research Groups
Hussein, M (author)
show more...
Bengtsson, Bo (author)
Lund University,Lunds universitet,Oftalmologi (Malmö),Forskargrupper vid Lunds universitet,Ophthalmology (Malmö),Lund University Research Groups
Hyman, L (author)
Komaroff, E (author)
show less...
 (creator_code:org_t)
American Medical Association (AMA), 2003
2003
English.
In: Archives of Ophthalmology. - : American Medical Association (AMA). - 0003-9950. ; 121:1, s. 48-56
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objective: To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including the effect of EMGT treatment. Setting/Participants: Two hundred fifty-five open-angle glaucoma patients randomized to argon laser trabeculoplasty plus topical betaxolol or no immediate treatment (129 treated; 126 controls) and followed up every 3 months. Methods: Progression was determined by perimetric and photographic optic disc criteria. Patient-based risk of progression was evaluated using Cox proportional hazard regression models and was expressed as hazard ratios (HR) with 95% confidence intervals (95% CI). Results: After 6 years, 53% of patients progressed. In multivariate analyses, progression risk was halved by treatment (HR=0.50; 95% CI, 0.35-0.71). Predictive baseline factors were higher intraocular pressure (IOP) (ie, the higher the baseline IOP, the higher the risk), exfoliation, and having both eyes eligible (each of the latter 2 factors doubled the risk), as well as worse mean deviation and older age. Progression risk decreased by about 10% with each millimeter of mercury of IOP reduction from baseline to the first follow-up visit (HR=0.90 per millimeter of mercury decrease; 95% CI, 0.86-0.94). The first IOP at that visit (3 months' follow-up) was also related to progression (HR=1.11 per millimeter of mercury higher; 95% CI, 1.06-1.17), as was the mean IOP at follow-up (HR=1.13 per millimeter of mercury higher; 95% CI, 1.07-1.19). The percent of patient follow-up visits with disc hemorrhages was also related to progression (HR=1.02 per percent higher; 95% CI, 1.01-1.03). No other factors were identified. Conclusions: Patients treated in the EMGT had half of the progression risk of control patients. The magnitude of initial IOP reduction was a major factor influencing outcome. Progression was also increased with higher baseline IOP, exfoliation, bilateral disease, worse mean deviation, and older age, as well as frequent disc hemorrhages during follow-up. Each higher (or lower) millimeter of mercury of IOP on follow-up was associated with an approximate 10% increased (or decreased) risk of progression.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Oftalmologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Ophthalmology (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Leske, MC
Heijl, Anders
Hussein, M
Bengtsson, Bo
Hyman, L
Komaroff, E
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Ophthalmology
Articles in the publication
Archives of Opht ...
By the university
Lund University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view